These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27318686)

  • 1. FDG and Beyond.
    De Ruysscher D; Haustermans K; Thorwarth D
    Recent Results Cancer Res; 2016; 198():163-73. PubMed ID: 27318686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From anatomical to biological target volumes: the role of PET in radiation treatment planning.
    Schinagl DA; Kaanders JH; Oyen WJ
    Cancer Imaging; 2006 Oct; 6(Spec No A):S107-16. PubMed ID: 17114062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. False-positive uptake on 2-[¹⁸F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging.
    Culverwell AD; Scarsbrook AF; Chowdhury FU
    Clin Radiol; 2011 Apr; 66(4):366-82. PubMed ID: 21356398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography for radiation treatment planning.
    Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
    Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?
    Basu S; Alavi A
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1527-9. PubMed ID: 17522857
    [No Abstract]   [Full Text] [Related]  

  • 7. The pivotal role of FDG-PET/CT in modern medicine.
    Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
    Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET in detecting primary breast cancer.
    Kumar R; Lal N; Alavi A
    J Nucl Med; 2007 Oct; 48(10):1751; author reply 1752. PubMed ID: 17909261
    [No Abstract]   [Full Text] [Related]  

  • 9. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodologic Considerations for Quantitative 18F-FDG PET/CT Studies of Hepatic Glucose Metabolism in Healthy Subjects.
    Trägårdh M; Møller N; Sørensen M
    J Nucl Med; 2015 Sep; 56(9):1366-71. PubMed ID: 26159590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignancies with Low Fluorodeoxyglucose Uptake at PET/CT: Pitfalls and Prognostic Importance: Resident and Fellow Education Feature.
    Flavell RR; Naeger DM; Aparici CM; Hawkins RA; Pampaloni MH; Behr SC
    Radiographics; 2016; 36(1):293-4. PubMed ID: 26761542
    [No Abstract]   [Full Text] [Related]  

  • 12. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shortened acquisition protocols for the quantitative assessment of the 2-tissue-compartment model using dynamic PET/CT 18F-FDG studies.
    Strauss LG; Pan L; Cheng C; Haberkorn U; Dimitrakopoulou-Strauss A
    J Nucl Med; 2011 Mar; 52(3):379-85. PubMed ID: 21321263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET-CT in oncology.
    Purandare NC; Rangarajan V
    J Postgrad Med; 2010; 56(2):103-8. PubMed ID: 20622389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of PET-CT fusion imaging in avoiding potential pitfalls in the interpretation of 18F-FDG accumulation in the distal oesophagus.
    Rampin L; Nanni C; Fanti S; Rubello D
    Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):990-2. PubMed ID: 15891918
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-Small-Cell Lung Cancer PET Imaging Beyond F18 Fluorodeoxyglucose.
    Cheng G
    PET Clin; 2018 Jan; 13(1):73-81. PubMed ID: 29157387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Searching for alternatives to full kinetic analysis in 18F-FDG PET: an extension of the simplified kinetic analysis method.
    Hapdey S; Buvat I; Carson JM; Carrasquillo JA; Whatley M; Bacharach SL
    J Nucl Med; 2011 Apr; 52(4):634-41. PubMed ID: 21421718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential role of non-FDG-PET in the management of head and neck cancer.
    Heuveling DA; de Bree R; van Dongen GA
    Oral Oncol; 2011 Jan; 47(1):2-7. PubMed ID: 21109481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
    Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
    Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.